Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5889-5900

  Rangger, Christine ^a   Helbok, Anna ^a   von Guggenberg, Elisabeth ^a   Sosabowski, Jane ^b   Radolf, Thorsten ^c   Prassl, Ruth ^d   Andreae, Fritz ^c   Thurner, Gudrun C ^a   Haubner, Roland ^a   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c piCHEM Research and Development   (Austria)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

v 3 integrin receptors; Angiogenesis; Liposomes; RGD peptides; Tumor targeting

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; ARGINYLGLYCYLASPARTIC ACID; CHOLESTEROL; INDIUM 111; IODINE 125; LIPOSOME; MACROGOL; NANOPARTICLE; PEGYLATED LIPOSOME; PENTETIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; DIAGNOSTIC AGENT; INDIUM; INDIUM CHLORIDE; MACROGOL DERIVATIVE; NANOCAPSULE; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CHEMISTRY; CRYSTALLIZATION; EXPERIMENTAL NEOPLASM; FEMALE; MATERIALS TESTING; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CRYSTALLIZATION; FEMALE; INDIUM; ISOTOPE LABELING; LIPOSOMES; MATERIALS TESTING; MICE; MICE, INBRED C57BL; MICE, NUDE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; ORGAN SPECIFICITY; POLYETHYLENE GLYCOLS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84875837284     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s36847     Document Type: Article

References (54)

1. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1): 238-252.
2. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;1(6):923-947.
3. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res. 2000; 39(5):461-475.
4. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
5. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101-2141.
6. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res. 2001;7(2):223-225.
7. Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178-181.
8. Tirosh O, Barenholz Y, Katzhendler J, Priev A. Hydration of polyethylene glycol-grafted liposomes. Biophys J. 1998;74(3):1371-1379.
9. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine. 2011;6:3087-3098.
10. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313.
11. Herringson TP, Altin JG. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int J Pharm. 2011;411(1-2):206-214.
12. Torchilin VP. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.
13. Lattin JR, Belnap DM, Pitt WG. Formation of eLiposomes as a drug delivery vehicle. Colloids Surf B Biointerfaces. 2012;89:93-100.
14. Ashley CE, Carnes EC, Phillips GK, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389-397.
15. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin α(v)β(3) expression. Eur J Nucl Med Mol Imaging. 2008;35(6):1100-1108.
16. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging. 2007;26(2):235-249.
17. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
18. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis -correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
19. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52(2):237-268.
20. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61(5):1781-1785.
21. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1): 9-22.
22. Helbok A, Decristoforo C, Dobrozemsky G, et al. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals. J Liposome Res. 2010;20(3):219-227.
23. Marik J, Tartis MS, Zhang H, et al. Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol. 2007;34(2):165-171.
24. Tsai CC, Chang CH, Chen LC, et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine. 2011;6:2607-2619.
25. Petersen AL, Binderup T, Jolck RI, et al. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J Control Release. 2012;160(2):254-263.
26. Jonasdottir TJ, Fisher DR, Borrebaek J, Bruland OS, Larsen RH. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res. 2006;26(4B):2841-2848.
27. Henriksen G, Schoultz BW, Michaelsen TE, Bruland OS, Larsen RH. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol. 2004;31(4):441-449.
28. Bard DR, Knight CG, Page-Thomas DP. Effect of the intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Clin Exp Rheumatol. 1985;3(3): 237-242.
29. McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci. 2005;7(4):29-34.
30. Mougin-Degraef M, Bourdeau C, Jestin E, et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm. 2007;344(1-2):110-117.
31. Rojas S, Gispert JD, Martin R, et al. Biodistribution of amino-functionalized diamond nanoparticles. In vivo studies based on 18F radionuclide emission. ACS Nano. 2011;5(7):5552-5559.
32. Nachman RL, Leung LL. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest. 1982;69(2): 263-269.
33. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80(4): 849-857.
34. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2(3):e70.
35. Su W, Wang H, Wang S, et al. PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. Int J Pharm. 2012;426(1-2):170-181.
36. Holig P, Bach M, Volkel T, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel. 2004;17(5):433-441.
37. Qin J, Chen D, Hu H, Qiao M, Zhao X, Chen B. Body distribution of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi. 2007;127(9):1497-1501.
38. Helbok A, Rangger C, Von Guggenberg E, et al. Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine. 2012;8(1):112-118.
39. Falciani C, Accardo A, Brunetti J, et al. Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. Chem Med Chem. 2011;6(4):678-685.
40. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992; 6(9):2716-2719.
41. Li S, Goins B, Zhang L, Bao A. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem. May 22, 2012. [Epub ahead of print.]
42. Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther. 2007;322(2):560-568.
43. Shokeen M, Pressly ED, Hagooly A, et al. Evaluation of multivalent, functional polymeric nanoparticles for imaging applications. ACS Nano. 2011;5(2):738-747.
44. Jiang J, Yang SJ, Wang JC, et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm. 2010;76(2):170-178.
45. Accardo A, Mansi R, Morisco A, et al. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol Biosyst. 2010;6(5): 878-887.
46. Mori A, Klibanov AL, Torchilin VP, Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 1991;284(2): 263-266.
47. Lehtinen J, Magarkar A, Stepniewski M, et al. Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine. Eur J Pharm Sci. 2012;46(3):121-130.
48. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem. 2006;49(20):6087-6093.
49. Laverman P, Brouwers AH, Dams ET, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther. 2000;293(3):996-1001.
50. Maherani B, Arab-Tehrany E, Kheirolomoom A, Reshetov V, Stebe MJ, Linder M. Optimization and characterization of liposome formulation by mixture design. Analyst. 2012;137(3):773-786.
51. Brinkhuis RP, Stojanov K, Laverman P, et al. Size dependent biodistribution and SPECT imaging of (111)In-labeled polymersomes. Bioconjug Chem. April 12, 2012. [Epub ahead of print.]
52. Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target. 2009;17(1):10-18.
53. Lestini BJ, Sagnella SM, Xu Z, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release. 2002;78(1-3):235-247.
54. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-6308.